Small number of healthy human subjects; investigates side effects and dose-response profiles; investigates metabolic and pharmacologic properties.

• A. Phase 2 Clinical Trial
• B. Ethics
• C. Phase 1 Clinical Trial
• D. Mammalian cells

Answer: (C)

The scenario describes early human testing focused on safety, dosing, and how the drug is processed and acts in the body. In Phase I trials, a small group of healthy volunteers is used to evaluate safety and tolerability, identify side effects, and explore dose-response relationships. Researchers also study metabolic and pharmacologic properties—essentially pharmacokinetics and pharmacodynamics—to understand how the body handles the drug and how the drug affects the body. This stage aims to establish a safe starting dose and gather initial information on absorption, distribution, metabolism, and excretion before testing in patients with the condition. The other options don’t fit this setup: ethics refer to study guidelines and approvals, mammalian cells point to preclinical lab work, and Phase II involves patients and focuses more on efficacy plus continued safety in a larger group.